200
Participants
Start Date
November 1, 2024
Primary Completion Date
November 1, 2026
Study Completion Date
November 1, 2028
Pyrotinib low dose group
Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Pyrotinib normal dose group
Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
The First People's Hospital of Xuzhou
OTHER
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
OTHER
The Second People's Hospital of Changshu
UNKNOWN
Shuyang County Traditional Chinese Medicine Hospital
UNKNOWN
Affiliated Hospital of Nantong University
OTHER
Affiliated Hospital of Jiangsu University
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER